Tade Brad L.
Known title: CFO and TreasurerCIK: 0002030561
Associated companies
Transaction History
| ADMA | ▼ Sell | Tax Withholding | 6,479 | $106K | 2/19/2026 | View on chart |
| ADMA | ▼ Sell | Tax Withholding | 7,123 | $123K | 7/24/2025 | View on chart |
| ADMA | ▼ Sell | Tax Withholding | 9,838 | $181K | 6/26/2025 | View on chart |
| ADMA | ▼ Sell | Tax Withholding | 5,280 | $83K | 2/26/2025 | View on chart |
| ADMA | ▲ Buy | Grant | 62,227 | $0 | 2/19/2025 | View on chart |
| ADMA | ▼ Sell | Open Market | 15,000 | $317K | 11/22/2024 | View on chart |
| ADMA | ▲ Buy | Grant | 72,400 | $0 | 7/24/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ADMA Biologics Draws Investor Attention Amid Market Decline
Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.
ADMA Biologics Draws Investor Attention Amid Market Decline. Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.